{"id":680279,"date":"2023-12-07T18:10:02","date_gmt":"2023-12-07T18:10:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=680279"},"modified":"2023-12-07T18:10:02","modified_gmt":"2023-12-07T18:10:02","slug":"alzheimers-disease-pipeline-fda-approvals-clinical-trials-developments-and-companies-2023","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/alzheimers-disease-pipeline-fda-approvals-clinical-trials-developments-and-companies-2023_680279.html","title":{"rendered":"Alzheimer\u2019s Disease Pipeline, FDA Approvals, Clinical Trials Developments, and Companies 2023"},"content":{"rendered":"<div style=\"float:right;  width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1701948072.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Alzheimer&rsquo;s Disease Pipeline, FDA Approvals, Clinical Trials Developments, and Companies 2023\" src=\"https:\/\/www.abnewswire.com\/uploads\/1701948072.jpeg\" alt=\"Alzheimer&rsquo;s Disease Pipeline, FDA Approvals, Clinical Trials Developments, and Companies 2023\" width=\"225\" height=\"225\" \/><\/a><\/div>\n<p style=\"text-align: justify;\">DelveInsight&rsquo;s, &ldquo;<strong>Alzheimer&rsquo;s Disease Pipeline Insights 2023<\/strong>&rdquo; report provides comprehensive insights about 150+ companies and 160+ pipeline drugs in Alzheimer&rsquo;s Disease pipeline landscape. It covers the Alzheimer&rsquo;s Disease pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Alzheimer&rsquo;s Disease pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.<\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Key Takeaways from the Alzheimer&rsquo;s Disease Pipeline Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>DelveInsight&rsquo;s Alzheimer&rsquo;s disease pipeline report depicts a robust space with 150+ active players working to develop 160+ pipeline therapies for Alzheimer&rsquo;s disease treatment.<\/li>\n<li>The leading companies working in the Alzheimer&rsquo;s disease Market include <em>Cassava Sciences, KeifeRx, AB Science, Eli Lilly and Company, BioVie Inc., AriBio Co., Ltd., Novo Nordisk, Alector Inc., Longeveron Inc., Cognition Therapeutics, TrueBinding, Inc., AbbVie, Shanghai Hengrui Pharmaceutical Co., Ltd.,<\/em> and others.<\/li>\n<li>Promising Alzheimer&rsquo;s disease Pipeline Therapies in the various stages of development include <em>PM012, Lecanemab 2.5 mg\/kg, Aricept (donepezil SR 23 mg), AL002, Rivastigmine transdermal patch, Simufilam<\/em>, and others.<\/li>\n<li><strong>November 2023: UCB Biopharma SRL<\/strong> announced a study of Phase 2 clinical trials for Bepranemab. The purpose of the study is to investigate the effect of bepranemab versus (vs) placebo on the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) up to Week 80 in study participants with prodromal or mild Alzheimer&#8217;s Disease (AD).<\/li>\n<li><strong>November 2023: Alector Inc<\/strong>. announced a study of Phase 2 clinical trials for AL002. This is a Phase 2, randomized, parallel-group, long-term extension (LTE), dose-blind, multicenter study to evaluate the long-term safety and efficacy of AL002 in participants with Early Alzheimer&#8217;s Disease. The study is a multicenter, global trial that will enroll participants who completed the planned treatment period in AL002-2 (parent study).<\/li>\n<li><strong>September 2023: Cassava Sciences Inc<\/strong>. announced a study of phase 3 clinical trials for Simufilam.The primary objective of this study is to investigate the safety and efficacy of simufilam (PTI-125) in enhancing cognition and slowing cognitive and functional decline following 76-week, repeat-dose oral administration in participants with mild-to-moderate AD.<\/li>\n<li><strong>September 2023: Alector Inc<\/strong>. announced a study of phase 2 clinical trials for AL002. A phase 2 randomized, double blind, placebo controlled study evaluating the efficacy and safety of AL002 in participants with Early Alzheimer&#8217;s Disease.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request a sample and discover the recent advances in Alzheimer&rsquo;s Disease Treatment Drugs @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/alzheimers-disease-ad-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">Alzheimer&rsquo;s Disease Pipeline Outlook Report<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\">In the Alzheimer&rsquo;s disease pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, Alzheimer&rsquo;s disease clinical trials studies, NDA approvals (if any), and product development activities comprising the technology, Alzheimer&rsquo;s Disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Alzheimer&rsquo;s Disease Overview<\/strong><\/p>\n<p style=\"text-align: justify;\">Dementia is a general term that refers to a decline in cognitive ability severe enough to interfere with activities of daily living. Alzheimer&#8217;s disease (AD) is the most common type of dementia, accounting for at least two-thirds of cases of dementia in people age 65 and older. Alzheimer&#8217;s disease is a neurodegenerative disease with insidious onset and progressive impairment of behavioral and cognitive functions including memory, comprehension, language, attention, reasoning, and judgment.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Find out more about Alzheimer&rsquo;s Disease Treatment Landscape @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/alzheimers-disease-ad-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">Drugs for Alzheimer&rsquo;s Disease Treatment<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Alzheimer&rsquo;s Disease Emerging Drugs Profile<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Nilotinib: KeifeRx<\/li>\n<li>AR1001: AriBio Co., Ltd.<\/li>\n<li>LY3372689: Eli Lilly &amp; Co<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Alzheimer&rsquo;s Disease Pipeline Therapeutics Assessment<\/strong><\/p>\n<p style=\"text-align: justify;\">There are approx. 150+ key companies which are developing the therapies for Alzheimer&rsquo;s Disease. The Alzheimer&rsquo;s Disease companies which have their Alzheimer&rsquo;s Disease drug candidates in the most advanced stage, i.e. phase III include, KeifeRx.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>DelveInsight&rsquo;s Alzheimer&rsquo;s Disease pipeline report covers around&nbsp;160+ products&nbsp;under different phases of clinical development like<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Late stage products (Phase III)<\/li>\n<li>Mid-stage products (Phase II)<\/li>\n<li>Early-stage product (Phase I) along with the details of<\/li>\n<li>Pre-clinical and Discovery stage candidates<\/li>\n<li>Discontinued &amp; Inactive candidates<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&emsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Alzheimer&rsquo;s Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Oral<\/li>\n<li>Parenteral<\/li>\n<li>Intravenous<\/li>\n<li>Subcutaneous<\/li>\n<li>Topical.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Alzheimer&rsquo;s Disease Products have been categorized under various Molecule types such as<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Monoclonal Antibody<\/li>\n<li>Peptides<\/li>\n<li>Polymer<\/li>\n<li>Small molecule<\/li>\n<li>Gene therapy<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Learn more about the emerging Alzheimer&rsquo;s Disease Pipeline Therapies @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/alzheimers-disease-ad-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">Alzheimer&rsquo;s Disease Clinical Trials Assessment<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Scope of the Alzheimer&rsquo;s Disease Pipeline Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Coverage- Global<\/li>\n<li>Alzheimer&rsquo;s Disease Therapeutic Assessment by Product Type: Mono, Combination, Mono\/Combination<\/li>\n<li>Alzheimer&rsquo;s Disease Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Alzheimer&rsquo;s Disease Companies- <em>Cassava Sciences, KeifeRx, AB Science, Eli Lilly and Company, BioVie Inc., AriBio Co., Ltd., Novo Nordisk, Alector Inc., Longeveron Inc., Cognition Therapeutics, TrueBinding, Inc., AbbVie, Shanghai Hengrui Pharmaceutical Co., Ltd<\/em>., and others.<\/li>\n<li>Alzheimer&rsquo;s disease Pipeline Therapies- <em>PM012, Lecanemab 2.5 mg\/kg, Aricept (donepezil SR 23 mg), AL002, Rivastigmine transdermal patch, Simufilam<\/em>, and others.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Dive deep into rich insights for new drugs for Alzheimer&rsquo;s Disease Treatment, Visit @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/alzheimers-disease-ad-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">Alzheimer&rsquo;s Disease Market Drivers and Barriers, and Future Perspective<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Table of Content<\/strong><\/p>\n<ol style=\"text-align: justify;\" start=\"1\">\n<li>Introduction<\/li>\n<li>Executive Summary<\/li>\n<li>Alzheimer&rsquo;s Disease: Overview<\/li>\n<li>Pipeline Therapeutics<\/li>\n<li>Therapeutic Assessment<\/li>\n<li>Alzheimer&rsquo;s Disease &ndash; DelveInsight&rsquo;s Analytical Perspective<\/li>\n<li>Late Stage Products (Phase III)<\/li>\n<li>Nilotinib: Novartis<\/li>\n<li>Drug profiles in the detailed report&hellip;..<\/li>\n<li>Mid Stage Products (Phase II)<\/li>\n<li>LY3372689: Eli Lilly &amp; Co.<\/li>\n<li>Drug profiles in the detailed report&hellip;..<\/li>\n<li>Early Stage Products (Phase I)<\/li>\n<li>Product Name: Company Name<\/li>\n<li>Drug profiles in the detailed report&hellip;..<\/li>\n<li>Inactive Products<\/li>\n<li>Alzheimer&rsquo;s Disease Key Companies<\/li>\n<li>Alzheimer&rsquo;s Disease Key Products<\/li>\n<li>Alzheimer&rsquo;s Disease- Unmet Needs<\/li>\n<li>Alzheimer&rsquo;s Disease- Market Drivers and Barriers<\/li>\n<li>Alzheimer&rsquo;s Disease- Future Perspectives and Conclusion<\/li>\n<li>Alzheimer&rsquo;s Disease Analyst Views<\/li>\n<li>Alzheimer&rsquo;s Disease Key Companies<\/li>\n<li>Appendix<\/li>\n<\/ol>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>For further information on the Alzheimer&rsquo;s Disease Pipeline Therapeutics, reach out @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/alzheimers-disease-ad-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">Alzheimer&rsquo;s Disease Unmet Needs and Analyst Views<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>About Us<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56402.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Yash Bhardwaj<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=alzheimers-disease-pipeline-fda-approvals-clinical-trials-developments-and-companies-2023\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304  S. Jones Blvd #2432<br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/report-store\/metastatic-melanoma-market\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/report-store\/metastatic-melanoma-market<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/report-store\/metastatic-melanoma-market\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=alzheimers-disease-pipeline-fda-approvals-clinical-trials-developments-and-companies-2023\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight&rsquo;s, &ldquo;Alzheimer&rsquo;s Disease Pipeline Insights 2023&rdquo; report provides comprehensive insights about 150+ companies and 160+ pipeline drugs in Alzheimer&rsquo;s Disease pipeline landscape. It covers the Alzheimer&rsquo;s Disease pipeline drug profiles, including clinical and nonclinical stage products. It also covers the &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/alzheimers-disease-pipeline-fda-approvals-clinical-trials-developments-and-companies-2023_680279.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[405,406,413],"tags":[],"class_list":["post-680279","post","type-post","status-publish","format-standard","hentry","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/680279","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=680279"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/680279\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=680279"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=680279"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=680279"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}